28 April 2022 (Thursday) - Transfusion News Update

Bits of plastic in our bloodstreams, HDN, and this week’s take on convalescent plasma… the Transfusion News update is always a good one…

Perfluoroalkyl and Polyfluoroalkyl Levels after Blood Donations

April 27, 2022Perfluoroalkyl and polyfluoroalkyl substances (PFASs) are ubiquitous synthetic compounds found in many products, including Teflon, water-resistant materials, paints, and firefighting foams. PFASs are commonly detected in biomonitoring studies in everything from air, water and soil to fish, animals, and human blood. Environmental and health agencies in Europe, the U.S., and Australia have identified PFASs as potential carcinogens and have linked them to several other adverse health effects. [Read More]


Guidelines for Hemolytic Disease of the Newborn

April 20, 2022 Hemolytic disease of the newborn (HDN) is a serious disease associated with significant morbidity and mortality. HDN occurs when maternal antibodies attack fetal red blood cells (RBCs) causing hemolysis; alloimmunization can occur to more than 50 antigens, but the most severe forms of HDN are associated with RhD, Rhc and K antigens. First-line treatments include phototherapy to help break down excess bilirubin and exchange transfusion to physically remove bilirubin. [Read More]


AABB Issues COVID-19 Convalescent Plasma Clinical Practice Guidelines

April 12, 2022 The use of COVID-19 convalescent plasma (CCP) has been highly controversial since the beginning of the pandemic. With the Food and Drug Administration’s approval and establishment of the Expanded Access Program, over 100,000 units of CCP were distributed to U.S. hospitals every month during the winter of 2020-2021 despite limited data on its efficacy. [Read More]


No comments:

Post a Comment